{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:19:17Z","timestamp":1777519157463,"version":"3.51.4"},"reference-count":52,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,23]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Patients with multiple myeloma (MM) and Waldenstr\u00f6m macroglobulinemia (WM) have increased risk of severe coronavirus disease 2019. Impaired humoral responses to the primary vaccination series against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been reported in patients with MM and WM, but the impact of booster vaccinations and functional status of the elicited antibodies are unknown. We performed a prospective cohort study investigating SARS-CoV-2 vaccination in patients with MM (n = 93) and WM (n = 48). The primary end point was effective immune response (EIR) at 28 days after the primary vaccination series (ie, anti\u2013spike SARS-CoV-2 antibody titer &amp;gt;250 U\/mL). The EIR rate after the primary vaccination series was 47% and 25% in patients with MM and WM, respectively. After the first and second booster vaccinations, the EIR rates increased to 84% and 91% in patients with MM and 60% and 89% in those with WM, respectively. Factors associated with lower EIR in patients with MM were hypogammaglobulinemia, lymphopenia, and treatment with anti-CD38 monoclonal antibody or corticosteroid. In patients with WM, treatment with a Bruton tyrosine kinase inhibitor or rituximab was associated with a lower EIR, whereas asymptomatic and treatment-na\u00efve patients had a higher EIR. Functional profiling identified reduced antibody-dependent cellular phagocytosis, neutrophil phagocytosis, and natural killer cell activity against wild-type and variant SARS-CoV-2 (Alpha, Beta, and Gamma) in patients with MM and WM compared to healthy donors. Our data demonstrate that although patients with MM and WM have impaired humoral responses to the primary SARS-CoV-2 vaccination series, repeated booster vaccines significantly improve immunogenicity. This trial was registered at www.ClinicalTrials.gov as #NCT04830046.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016513","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T16:04:31Z","timestamp":1749139471000},"page":"4568-4579","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenstr\u00f6m macroglobulinemia"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3868-9267","authenticated-orcid":false,"given":"Andrew R.","family":"Branagan","sequence":"first","affiliation":[{"name":"1Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clifton","family":"Mo","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5348-6065","authenticated-orcid":false,"given":"Matthew","family":"Lei","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua N.","family":"Gustine","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3623-7491","authenticated-orcid":false,"given":"Andrew J.","family":"Yee","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9490-7532","authenticated-orcid":false,"given":"Jorge J.","family":"Castillo","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Nadeem","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Flynn","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Bernstein","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0166-7727","authenticated-orcid":false,"given":"Rie","family":"Nakamoto-Matsubara","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten","family":"Meid","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1523-557X","authenticated-orcid":false,"given":"Rakesh","family":"Verma","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1689-1691","authenticated-orcid":false,"given":"Zachary R.","family":"Hunter","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria L.","family":"Guerrera","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galit","family":"Alter","sequence":"additional","affiliation":[{"name":"3Division of Medical Sciences, Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Burke","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Harrington","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emerentia","family":"Agyemang","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyn","family":"Gammon","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Lively","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisette","family":"Packer","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora","family":"Horick","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7565-2052","authenticated-orcid":false,"given":"Jacob","family":"Laubach","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantine S.","family":"Mitsiades","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Munshi","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6393-6154","authenticated-orcid":false,"given":"Steven P.","family":"Treon","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noopur S.","family":"Raje","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shayna R.","family":"Sarosiek","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"issue":"1","key":"2025092310365989500_bib1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"issue":"21","key":"2025092310365989500_bib2","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1182\/blood.V124.21.3350.3350","article-title":"Patterns of infectious morbidity in patients with Waldenstr\u00f6m\u2019s macroglobulinaemia\/lymphoplasmacytic lymphoma: a population-based study","volume":"124","author":"Lund","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2025092310365989500_bib3","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1086\/605664","article-title":"Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents","volume":"49","author":"Nucci","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2025092310365989500_bib4","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/bjh.16492","article-title":"Cause-specific mortality in individuals with lymphoplasmacytic lymphoma\/Waldenstr\u00f6m macroglobulinaemia, 2000-2016","volume":"189","author":"Dalal","year":"2020","journal-title":"Br J Haematol"},{"issue":"2","key":"2025092310365989500_bib5","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"issue":"3","key":"2025092310365989500_bib6","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3324\/haematol.2009.010348","article-title":"IgA and IgG hypogammaglobulinemia in Waldenstr\u00f6m's macroglobulinemia","volume":"95","author":"Hunter","year":"2010","journal-title":"Haematologica"},{"issue":"2","key":"2025092310365989500_bib7","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1046\/j.1365-2249.2001.01582.x","article-title":"Deregulated cytokine network and defective Th1 immune response in multiple myeloma","volume":"125","author":"Frassanito","year":"2001","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"2025092310365989500_bib8","doi-asserted-by":"crossref","first-page":"553","DOI":"10.4049\/jimmunol.167.1.553","article-title":"Suppression of IL-2-induced T cell proliferation and phosphorylation of STAT3 and STAT5 by tumor-derived TGF beta is reversed by IL-15","volume":"167","author":"Campbell","year":"2001","journal-title":"J Immunol"},{"issue":"1","key":"2025092310365989500_bib9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2005-08-3101","article-title":"Dysfunctional T regulatory cells in multiple myeloma","volume":"107","author":"Prabhala","year":"2006","journal-title":"Blood"},{"issue":"9","key":"2025092310365989500_bib10","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.3324\/haematol.2020.277525","article-title":"Myeloma natural killer cells are exhausted and have impaired regulation of activation","volume":"106","author":"D'Souza","year":"2021","journal-title":"Haematologica"},{"issue":"4","key":"2025092310365989500_bib11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ajh.2830110402","article-title":"Alternative pathway of complement in multiple myeloma","volume":"11","author":"Kraut","year":"1981","journal-title":"Am J Hematol"},{"issue":"1","key":"2025092310365989500_bib12","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/s41467-025-56323-w","article-title":"Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom's macroglobulinemia","volume":"16","author":"Sklavenitis-Pistofidis","year":"2025","journal-title":"Nat Commun"},{"issue":"6","key":"2025092310365989500_bib13","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood-2015-01-553974","article-title":"How I treat Waldenstr\u00f6m macroglobulinemia","volume":"126","author":"Treon","year":"2015","journal-title":"Blood"},{"issue":"27","key":"2025092310365989500_bib14","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2018.78.6426","article-title":"Ibrutinib monotherapy in symptomatic, treatment-na\u00efve patients with Waldenstr\u00f6m macroglobulinemia","volume":"36","author":"Treon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025092310365989500_bib15","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/annonc\/mdi022","article-title":"Extended rituximab therapy in Waldenstr\u00f6m's macroglobulinemia","volume":"16","author":"Treon","year":"2005","journal-title":"Ann Oncol"},{"issue":"9","key":"2025092310365989500_bib16","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2217\/imt.15.66","article-title":"Modulatory effects of bortezomib on host immune cell functions","volume":"7","author":"Pellom","year":"2015","journal-title":"Immunotherapy"},{"issue":"5","key":"2025092310365989500_bib17","doi-asserted-by":"crossref","first-page":"e64354","DOI":"10.1371\/journal.pone.0064354","article-title":"Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Yang","year":"2013","journal-title":"PLoS One"},{"issue":"13","key":"2025092310365989500_bib18","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"2025092310365989500_bib19","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1470-2045(24)00094-9","article-title":"Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee [published correction appears in Lancet Oncol. 2024;25(8):e336]","volume":"25","author":"Lin","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"2025092310365989500_bib20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/bjh.13532","article-title":"Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy","volume":"171","author":"Teh","year":"2015","journal-title":"Br J Haematol"},{"issue":"6","key":"2025092310365989500_bib21","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/CVI.00021-11","article-title":"Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom's macroglobulinemia, and monoclonal gammopathy of undetermined significance","volume":"18","author":"Karlsson","year":"2011","journal-title":"Clin Vaccin Immunol"},{"issue":"7","key":"2025092310365989500_bib22","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1054\/bjoc.1999.1088","article-title":"Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma","volume":"82","author":"Robertson","year":"2000","journal-title":"Br J Cancer"},{"issue":"7","key":"2025092310365989500_bib23","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.3324\/haematol.2014.116772","article-title":"Efficacy of single versus boost vaccination against influenza virus in patients with multiple myeloma","volume":"100","author":"Hahn","year":"2015","journal-title":"Haematologica"},{"issue":"5","key":"2025092310365989500_bib24","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.clml.2017.02.025","article-title":"Clinical and serologic responses after a two-dose series of high-dose influenza vaccine in plasma cell disorders: a prospective, single-arm trial","volume":"17","author":"Branagan","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"2025092310365989500_bib25","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1182\/blood-2024-202102","article-title":"A randomized trial demonstrates a 3-shot flu vaccine series improves protection over a single shot in multiple myeloma","volume":"144","author":"Hofmeister","year":"2024","journal-title":"Blood"},{"issue":"25","key":"2025092310365989500_bib26","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1182\/blood.2020008824","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients","volume":"136","author":"Vijenthira","year":"2020","journal-title":"Blood"},{"issue":"2","key":"2025092310365989500_bib27","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/bjh.17608","article-title":"Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma","volume":"195","author":"Avivi","year":"2021","journal-title":"Br J Haematol"},{"issue":"6","key":"2025092310365989500_bib28","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3026(21)00110-1","article-title":"Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma","volume":"8","author":"Bird","year":"2021","journal-title":"Lancet Haematol"},{"issue":"12","key":"2025092310365989500_bib29","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1038\/s41375-021-01354-7","article-title":"Response to mRNA vaccination for COVID-19 among patients with multiple myeloma","volume":"35","author":"Stampfer","year":"2021","journal-title":"Leukemia"},{"issue":"24","key":"2025092310365989500_bib30","doi-asserted-by":"crossref","first-page":"6198","DOI":"10.1182\/bloodadvances.2022008530","article-title":"Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis","volume":"6","author":"Chuleerarux","year":"2022","journal-title":"Blood Adv"},{"issue":"21","key":"2025092310365989500_bib31","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1182\/bloodadvances.2021005444","article-title":"Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study","volume":"5","author":"Gavriatopoulou","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"2025092310365989500_bib32","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/bjh.18055","article-title":"Response to vaccination against SARS-CoV-2 in 168 patients with Waldenstr\u00f6m macroglobulinaemia: a French Innovative Leukaemia Organization study","volume":"197","author":"Tomowiak","year":"2022","journal-title":"Br J Haematol"},{"issue":"1","key":"2025092310365989500_bib33","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ccell.2021.12.003","article-title":"Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia","volume":"40","author":"Konishi","year":"2022","journal-title":"Cancer Cell"},{"issue":"26","key":"2025092310365989500_bib34","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1200\/JCO.21.02257","article-title":"Determinants of neutralizing antibody response after SARS CoV-2 vaccination in patients with myeloma","volume":"40","author":"Nooka","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025092310365989500_bib35","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1182\/bloodadvances.2021006627","article-title":"Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study","volume":"6","author":"Haydu","year":"2022","journal-title":"Blood Adv"},{"issue":"9","key":"2025092310365989500_bib36","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood.2021014989","article-title":"Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy","volume":"139","author":"Terpos","year":"2022","journal-title":"Blood"},{"issue":"20","key":"2025092310365989500_bib37","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 - preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"issue":"7830","key":"2025092310365989500_bib38","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"2025092310365989500_bib39","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s12879-016-1648-2","article-title":"Epidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factors","volume":"16","author":"Backhaus","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"7","key":"2025092310365989500_bib40","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1182\/blood.2022016317","article-title":"Increased COVID-19 breakthrough infection risk in patients with plasma cell disorders","volume":"140","author":"La","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2025092310365989500_bib41","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood.2021013429","article-title":"Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma","volume":"139","author":"En\u00dfle","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2025092310365989500_bib42","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/bjh.18434","article-title":"Antibody and T-cell responses by ultra-deep T-cell receptor immunosequencing after COVID-19 vaccination in patients with plasma cell dyscrasias","volume":"199","author":"Chung","year":"2022","journal-title":"Br J Haematol"},{"issue":"3","key":"2025092310365989500_bib43","doi-asserted-by":"crossref","first-page":"106432","DOI":"10.1016\/j.jinf.2025.106432","article-title":"Immunocompromised individuals remain at risk of COVID-19: 2023 results from the observational INFORM study","volume":"90","author":"Quint","year":"2025","journal-title":"J Infect"},{"issue":"6","key":"2025092310365989500_bib44","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1182\/blood.2021013714","article-title":"Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma","volume":"139","author":"Henriquez","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2025092310365989500_bib45","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41408-021-00530-3","article-title":"The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment","volume":"11","author":"Terpos","year":"2021","journal-title":"Blood Cancer J"},{"issue":"3","key":"2025092310365989500_bib46","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/jha2.724","article-title":"Immune response to COVID-19 vaccination in patients with Waldenstr\u00f6m macroglobulinaemia who pause their BTKi therapy","volume":"4","author":"Rankin","year":"2023","journal-title":"EJHaem"},{"issue":"10","key":"2025092310365989500_bib47","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.3324\/haematol.2018.191999","article-title":"Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenstr\u00f6m macroglobulinemia","volume":"103","author":"Castillo","year":"2018","journal-title":"Haematologica"},{"issue":"7","key":"2025092310365989500_bib48","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.3324\/haematol.2017.186908","article-title":"Ibrutinib withdrawal symptoms in patients with Waldenstr\u00f6m macroglobulinemia","volume":"103","author":"Castillo","year":"2018","journal-title":"Haematologica"},{"issue":"3","key":"2025092310365989500_bib49","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"2025092310365989500_bib50","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/leu.2015.356","article-title":"Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group","volume":"30","author":"Laubach","year":"2016","journal-title":"Leukemia"},{"key":"2025092310365989500_bib51","doi-asserted-by":"crossref","first-page":"101218","DOI":"10.1016\/j.blre.2024.101218","article-title":"Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide","volume":"66","author":"Mo","year":"2024","journal-title":"Blood Rev"},{"issue":"10","key":"2025092310365989500_bib52","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.3324\/haematol.2024.285345","article-title":"Use of defibrotide in COVID-19 pneumonia: comparison of a phase II study and a matched real-world cohort control","volume":"109","author":"Ruggeri","year":"2024","journal-title":"Haematologica"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/18\/4568\/2411505\/blooda_adv-2025-016513-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/18\/4568\/2411505\/blooda_adv-2025-016513-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:37:08Z","timestamp":1758638228000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/18\/4568\/537631\/Prospective-study-of-immunogenicity-to-SARS-CoV-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":52,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025,9,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016513","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,23]]},"published":{"date-parts":[[2025,9,10]]}}}